Fulcrum’s Sickle Cell Drug Shows Major Promise, Backed by $352M War Chest

CAMBRIDGE, MA – February 24, 2026 – Fulcrum Therapeutics has unveiled compelling new clinical data for its sickle cell disease (SCD) drug candidate, pociredir, alongside a robust financial update that positions the company for long-term development. The announcement signals a dual victory for the Cambridge-based biopharmaceutical firm: promising scientific progress for a debilitating genetic disorder and the financial stability to see it through pivotal late-stage trials.

In its latest report, Fulcrum detailed positive 12-week results from its Phase 1b PIONEER trial, which showed that pociredir significantly increased fetal hemoglobin (HbF) in patients with SCD. Simultaneously, the company reported ending 2025 with over $352 million in cash, extending its operational runway into 2029. This combination of clinical momentum and financial fortification sharpens the company’s focus on what could become a transformative oral therapy for the SCD community.

“Building on the previously reported interim data presented in December at ASH, the positive 12-week data from the complete 20 mg cohort of the PIONEER trial reinforce our conviction in pociredir’s potential to address the underlying biology of sickle cell disease,” said Alex C. Sapir, Fulcrum’s President and Chief Executive Officer, in a statement. The results are a critical step forward as the company prepares for discussions with the U.S. Food and Drug Administration (FDA).

A New Hope in an Oral Pill

Sickle cell disease is a painful, life-long genetic condition caused by a mutation that leads red blood cells to form a rigid, sickle shape. These cells can block blood flow, causing excruciating pain episodes known as vaso-occlusive crises (VOCs), organ damage, and a shortened life expectancy. A key therapeutic strategy is to increase the production of fetal hemoglobin (HbF), a form of hemoglobin present at birth that is highly effective at carrying oxygen and interferes with the sickling process.

The latest data from the PIONEER trial’s 20 mg cohort of 12 patients demonstrates that pociredir, an oral small-molecule inhibitor, is a potent inducer of HbF. The results showed a mean absolute HbF increase of 12.2%, elevating levels from a baseline of 7.1% to an impressive 19.3% by week 12. According to data previously presented by Fulcrum, achieving HbF levels around 20% is associated with a dramatic reduction in VOCs for a majority of patients.

Beyond the headline number, the trial also showed progression toward pan-cellular HbF induction—meaning the protective fetal hemoglobin was being distributed across a greater number of red blood cells. This is a crucial factor for therapeutic efficacy. Patients also saw improvements in markers of hemolysis (the destruction of red blood cells) and anemia, with an average increase of more than 1 g/dL in total hemoglobin. Encouragingly, pociredir was generally well-tolerated, with no treatment-related serious adverse events reported.

Navigating a Crowded and Shifting Market

The treatment landscape for sickle cell disease is undergoing a dramatic transformation. The recent landmark approvals of Casgevy and Lyfgenia—two revolutionary gene therapies—have offered the potential for a cure. However, these treatments involve a complex, expensive, and arduous process that includes chemotherapy to wipe out a patient's bone marrow before transplanting their own genetically modified stem cells. This makes them unsuitable or inaccessible for a large portion of the patient population.

This is where pociredir could carve out a significant niche. As an oral, once-daily pill, it represents a far more accessible treatment modality. Its potential success is further highlighted by the recent stumbles of other therapies. Pfizer recently withdrew its drug Oxbryta from the market due to safety concerns, and Novartis's Adakveo had its European approval revoked after failing to show sufficient efficacy in a post-market study. This shifting landscape has created a clear opening for a safe, effective, and convenient oral therapy that can fundamentally alter the course of the disease.

Pociredir’s mechanism, which inhibits a protein called Embryonic Ectoderm Development (EED) to switch on HbF production, targets the root cause of the disease in a novel way. If its promising early results are replicated in larger trials, it could offer a powerful alternative for the vast majority of SCD patients who are not candidates for gene therapy.

A Focused Strategy and a Fortified Balance Sheet

Clinical promise is only one part of the drug development equation; financial endurance is the other. Fulcrum has strategically bolstered its financial position to support pociredir's path to market. A successful public offering in December 2025 netted the company $164.2 million, contributing to a total cash reserve of $352.3 million at year's end.

This financial strength has enabled the company to make decisive strategic choices. Fulcrum announced it would discontinue development of a program for bone marrow failure syndromes to concentrate its resources on pociredir and its core benign hematology pipeline. This move signals immense confidence in pociredir's potential and reassures investors that the company is laser-focused on its lead asset.

With a cash runway projected to last into 2029, Fulcrum is in an enviable position. This long-term financial security allows the company to plan and execute a comprehensive late-stage clinical program without the near-term pressure of raising additional capital, a significant advantage in the volatile biotech market. The company’s full-year net loss widened to $74.9 million in 2025, but this reflects a deliberate increase in R&D spending to advance the PIONEER trial, a strategic investment in its future.

The Path to Patients

With strong Phase 1b data in hand, Fulcrum is now preparing for the most critical phase of development. The company plans to meet with the FDA for an End-of-Phase meeting and, pending regulatory alignment, intends to launch a potential registration-enabling trial in the second half of 2026. A registration-enabling trial is designed with the specific goal of gathering the necessary data to apply for marketing approval.

Pociredir already benefits from Fast Track and Orphan Drug designations from the FDA. These designations are designed to expedite the development and review of drugs for serious conditions with unmet medical need, potentially shortening the timeline to get the therapy to patients. Fulcrum expects to provide more details on the design of this pivotal next trial in the second quarter of this year, following receipt of official minutes from its FDA meeting.

For the thousands of individuals and families affected by sickle cell disease, the journey of pociredir represents a new wave of hope. As Fulcrum pairs its promising clinical results with a clear-eyed strategy and a fortified balance sheet, the path toward a new, accessible standard of care appears more defined than ever.